CARDIOVASCULAR JOURNAL OF AFRICA • Volume 35, No 2, May – August 2024 114 AFRICA Eugene Marais Hospital in Pretoria, Chris Hani Baragwanath Hospital in Johannesburg, Groote Schuur Hospital and Mediclinic Panorama in Cape Town, Milpark Hospital in Parktown West, Netcare Greenacres Hospital in Port Elizabeth and Life St Dominic’s Hospital in East London, South Africa for their support in the enrolment of patients in the GSR. This work was supported by Medtronic, Inc. M Ntsekhe receives research money from Medtronic. Brian Rayner has received consulting fees and speaker honoraria from Servier, Astra-Zeneca, Boehringer-Ingelheim, Astellas, Merck and Novartis. M Fahy is a full-time employee and shareholder of Medtronic. G Mancia reports consulting fees and speaker’s honoraria from Astra-Zeneca, Berlin Chemie, Böhriner Ingelheim, Gedeon Richter, Medtronic Vascular Inc, Menarini Int, Merck Healthcare KGaA, Medtronic Inc, USA, Neopharmed-Gentili, Novartis Pharma, Recordati, Sandoz, Sanofi and Servier. M Böhm is supported by the Deutsche Forschungsgemeinschaft (TTR 219, project number 322900939) and reports personal fees from Abbott, Amgen, Astra-Zeneca, Bayer, Boehringer Ingelheim, Cytokinetics, Medtronic, Novartis, Servier and Vifor. References 1. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365(9455): 217–223. 2. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. J Am Med Assoc 2010; 303(20): 2043–2050. 3. Lloyd-Jones DM, Evans JC, Levy D. Hypertension in adults across the age spectrum: current outcomes and control in the community. J Am Med Assoc 2005; 294(4): 466–472. 4. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective Studies C. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360(9349): 1903–1913. 5. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008; 117(25): e510–526. 6. Persell SD. Prevalence of resistant hypertension in the United States, 2003–2008. Hypertension 2011; 57(6): 1076–1080. 7. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; 28(12): 1462–1536. 8. Rosendorff C, Black HR, Cannon CP, Gersh BJ, Gore J, Izzo JL, Jr, et al. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation 2007; 115(21): 2761–2788. 9. Ostchega Y, Yoon SS, Hughes J, Louis T. Hypertension awareness, treatment, and control – continued disparities in adults: United States, 2005–2006. NCHS Data Brief 2008; 3: 1–8. 10. DiBona GF, Esler M. Translational medicine: the antihypertensive effect of renal denervation. Am J Physiol Regul Integr Comp Physiol 2010; 298(2): R245–253. 11. Azizi M, Schmieder RE, Mahfoud F, Weber MA, Daemen J, Davies J, et al. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet 2018; 391(10137): 2335–2345. 12. Kandzari DE, Bohm M, Mahfoud F, Townsend RR, Weber MA, Pocock S, et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet 2018; 391(10137): 2346–2355. 13. Bohm M, Kario K, Kandzari DE, Mahfoud F, Weber MA, Schmieder RE, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet 2020; 395(10234): 1444–1451. 14. Heradien MJ, Van der Bijl P, Brink PA. Renal denervation in South Africa. S Afr Med J 2020; 110(2): 12841. 15. Gomez-Olive FX, Ali SA, Made F, Kyobutungi C, Nonterah E, Micklesfield L, et al. Regional and sex differences in the prevalence and awareness of hypertension: an H3Africa AWI-Gen study across 6 sites in sub-Saharan Africa. Glob Heart 2017; 12(2): 81–90. 16. Bohm M, Mahfoud F, Ukena C, Bauer A, Fleck E, Hoppe UC, et al. Rationale and design of a large registry on renal denervation: the Global SYMPLICITY registry. EuroIntervention 2013; 9(4): 484–492. 17. Bohm M, Mahfoud F, Ukena C, Hoppe UC, Narkiewicz K, Negoita M, et al. First report of the Global SYMPLICITY Registry on the effect of renal artery denervation in patients with uncontrolled hypertension. Hypertension 2015; 65(4): 766–774. 18. Kim BK, Bohm M, Mahfoud F, Mancia G, Park S, Hong MK, et al. Renal denervation for treatment of uncontrolled hypertension in an Asian population: results from the Global SYMPLICITY Registry in South Korea (GSR Korea). J Hum Hypertens 2016; 30(5): 315–321. 19. Lee CK, Wang TD, Lee YH, Fahy M, Lee CH, Sung SH, et al. Efficacy and safety of renal denervation for patients with uncontrolled hypertension in Taiwan: 3-year results from the Global SYMPLICITY RegistryTaiwan (GSR-Taiwan). Acta Cardiol Sin 2019; 35(6): 618–626. 20. O’Brien E, Parati G, Stergiou G, Asmar R, Beilin L, Bilo G, et al. European Society of Hypertension position paper on ambulatory blood pressure monitoring. J Hypertens 2013; 31(9): 1731–1768. 21. Bhatt DL, Kandzari DE, O’Neill WW, D’Agostino R, Flack JM, Katzen BT, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med 2014; 370(15): 1393–13401. 22. Townsend RR, Mahfoud F, Kandzari DE, Kario K, Pocock S, Weber MA, et al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proofof-concept trial. Lancet 2017; 390(10108): 2160–2170. 23. Mahfoud F, Mancia G, Schmieder R, Narkiewicz K, Ruilope L, Schlaich M, et al. Renal denervation in high-risk patients with hypertension. J Am Coll Cardiol 2020; 75(23): 2879–2888. 24. Ott C, Mahfoud F, Mancia G, Narkiewicz K, Ruilope LM, Fahy M, et al. Renal denervation in patients with versus without chronic kidney disease: results from the global SYMPLICITY Registry with follow-up data of 3 years. Nephrol Dial Transplant 2022; 37(2): 304–310. 25. Rayner B. Hypertension: detection and management in South Africa. Nephron Clin Pract 2010; 116(4): c269–273.
RkJQdWJsaXNoZXIy NDIzNzc=